Humacyte, Inc. (HUMA)

NASDAQ: HUMA · IEX Real-Time Price · USD
3.100
+0.030 (0.98%)
At close: Mar 27, 2024, 4:00 PM
3.130
+0.030 (0.97%)
After-hours: Mar 27, 2024, 7:58 PM EDT

Total Valuation

Humacyte has a market cap or net worth of $359.11 million. The enterprise value is $315.91 million.

Market Cap 359.11M
Enterprise Value 315.91M

Important Dates

The last earnings date was Friday, March 22, 2024, before market open.

Earnings Date Mar 22, 2024
Ex-Dividend Date n/a

Share Statistics

Humacyte has 116.98 million shares outstanding. The number of shares has increased by 0.40% in one year.

Shares Outstanding 116.98M
Shares Change (YoY) +0.40%
Shares Change (QoQ) +0.08%
Owned by Insiders (%) 32.03%
Owned by Institutions (%) 15.54%
Float 71.00M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS 525.68
PB Ratio 9.71
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.80, with a Debt / Equity ratio of 1.53.

Current Ratio 6.80
Quick Ratio n/a
Debt / Equity 1.53
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -12.73

Financial Efficiency

Return on equity (ROE) is -120.40% and return on invested capital (ROIC) is -100.94%.

Return on Equity (ROE) -120.40%
Return on Assets (ROA) -50.70%
Return on Capital (ROIC) -100.94%
Revenue Per Employee n/a
Profits Per Employee -$545,061
Employee Count 164
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -4.32% in the last 52 weeks. The beta is 1.52, so Humacyte's price volatility has been higher than the market average.

Beta (1Y) 1.52
52-Week Price Change -4.32%
50-Day Moving Average 3.50
200-Day Moving Average 3.08
Relative Strength Index (RSI) 41.56
Average Volume (30 Days) 906,301

Short Selling Information

The latest short interest is 3.78 million, so 3.23% of the outstanding shares have been sold short.

Short Interest 3.78M
Short Previous Month 5.95M
Short % of Shares Out 3.23%
Short % of Float 5.33%
Short Ratio (days to cover) 6.60

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -94.66M
Pretax Income -89.39M
Net Income -89.39M
EBITDA -74.83M
EBIT -82.88M
Earnings Per Share (EPS) -$0.87
Full Income Statement

Balance Sheet

The company has $99.99 million in cash and $56.78 million in debt, giving a net cash position of $43.21 million or $0.37 per share.

Cash & Cash Equivalents 99.99M
Total Debt 56.78M
Net Cash 43.21M
Net Cash Per Share $0.37
Equity / Book Value 36.99M
Book Value Per Share 0.32
Working Capital 87.71M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$73.21 million and capital expenditures -$2.81 million, giving a free cash flow of -$76.02 million.

Operating Cash Flow -73.21M
Capital Expenditures -2.81M
Free Cash Flow -76.02M
FCF Per Share -$0.74
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -0.40%
Shareholder Yield -0.40%
Earnings Yield -24.89%
FCF Yield -21.17%

Analyst Forecast

The average price target for Humacyte is $7.00, which is 125.81% higher than the current price. The consensus rating is "Buy".

Price Target $7.00
Price Target Difference 125.81%
Analyst Consensus Buy
Analyst Count 5
Revenue Growth Forecast (5Y) 149.00%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1